Laura Sepp-Lorenzino - Jan 3, 2025 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
EVP, Chief Scientific Officer
Signature
James Basta, attorney-in-fact
Stock symbol
NTLA
Transactions as of
Jan 3, 2025
Transactions value $
-$109,206
Form type
4
Date filed
1/7/2025, 05:16 PM
Previous filing
Jan 3, 2025
Next filing
Jun 4, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Sale -$109K -8.97K -10.38% $12.18 77.4K Jan 3, 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2025, and does not represent a volitional trade by the Reporting Person.